ArkBio Launches Phase II Trial of AK0610 RSV Antibody
Shanghai Ark Biopharmaceutical Co., Ltd., also referred to as ArkBio, has announced the start of a Phase II clinical trial for AK0610, a fully human monoclonal antibody aimed at...